<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/0235-2990-2026-71-5-6-25-33</article-id><article-id custom-type="edn" pub-id-type="custom">XIDLDA</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-1403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Прогностический потенциал фармакокинетико-фармакодинамических параметров при оценке эффекта дорипенема и левофлоксацина в отношении Pseudomonas aeruginosa в динамической системе in vitro</article-title><trans-title-group xml:lang="en"><trans-title>Predictive Potential of Pharmacokinetic-Pharmacodynamic Parameters in Evaluation of Doripenem and Levofloxacin Effects: A Study in an in vitro Dynamic Model with Pseudomonas aeruginosa</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5391-1137</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Струкова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Strukova</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Струкова Елена Николаевна — к. б. н., с. н. с. лаборатории фармакокинетики и фармакодинамики</p><p>Москва</p></bio><bio xml:lang="en"><p>Elena N. Strukova — Ph. D. in Biology, Senior Researcher at the Laboratory of Pharmacokinetics and Pharmacodynamics</p><p>Moscow</p></bio><email xlink:type="simple">kindyn@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7588-1733</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голикова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golikova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голикова Мария Владимировна — к. б. н., с. н. с., заведующая лабораторией фармакокинетики и фармакодинамики </p><p>Москва</p></bio><bio xml:lang="en"><p>Maria V. Golikova — Ph. D. in Biology, Senior Researcher, Head of the Laboratory of Pharmacokinetics and Pharmacodynamics</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2107-8259</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиева</surname><given-names>К. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Alieva</surname><given-names>K. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алиева Камилла Натиговна — к. б. н., н. с. лаборатории фармакокинетики и фармакодинамики</p><p>Москва</p></bio><bio xml:lang="en"><p>Kamilla N. Alieva — Ph. D. in Biology, Researcher at the Laboratory of Pharmacokinetics and Pharmacodynamics</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт по изысканию новых антибиотиков им. Г. Ф. Гаузе»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Gause Institute of New Antibiotics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт по изысканию новых&#13;
антибиотиков им. Г. Ф. Гаузе</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Gause Institute of New Antibiotics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт по изысканию новых антибиотиков им. Г. Ф. Гаузе</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Gause Institute of New Antibiotics</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2026</year></pub-date><volume>71</volume><issue>5-6</issue><fpage>25</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ООО «Издательство ОКИ», 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">ООО «Издательство ОКИ»</copyright-holder><copyright-holder xml:lang="en">ООО «Издательство ОКИ»</copyright-holder><license xlink:href="https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/1403">https://www.antibiotics-chemotherapy.ru/jour/article/view/1403</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Деление антибиотиков на «время-зависимые», «концентрационно-зависимые» и «концентрационно-время-зависимые» на основе корреляции их эффективности с фармакокинетико-фармакодинамическими (ФК/ФД) параметрами: T&gt;МПК (доля интервала дозирования, в течение которого концентрация антибиотика превышает МПК), CМАКС/МПК (отношение максимальной концентрации к МПК), либо ПФК/МПК (отношение площади под фармакокинетической кривой к минимальной подавляющей концентрации), в настоящее время подвергается существенному пересмотру.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Изучение зависимостей между значениями ПФК/МПК и T&gt;МПК и уровнями эффекта дорипенема и левофлоксацина в отношении Pseudomonas aeruginosa в динамической системе in vitro.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Клинические штаммы P. aeruginosa 180 и P. aeruginosa 52 подвергали воздействию дорипенема или левофлоксацина при разных режимах введения антибиотиков, включая терапевтический, в динамической системе in vitro на протяжении 5 дней. Оценивали антимикробный эффект с помощью интегрального параметра AUBC и строили зависимости между эффектом каждого антибиотика и ПФК/МПК или T&gt;МПК. Наличие статистически значимой зависимости служит доказательством способности параметра прогнозировать эффект.</p></sec><sec><title>Результаты</title><p>Результаты. Максимальный антимикробный эффект дорипенема наблюдали при моделировании терапевтической дозы антибиотика, в то время как сопоставимый эффект левофлоксацина был достижим при моделировании двойной терапевтической дозы и только для одного штамма P. aeruginosa. Зависимости «эффект — ПФК/МПК или T&gt;МПК» описывали уравнением Хилла, в случае дорипенема с одинаково высокими r2, а в случае левофлоксацина достоверная связь была установлена только с параметром ПФК/МПК.</p></sec><sec><title>Заключение</title><p>Заключение. Согласно нашим результатам, ФК/ФД параметром, связанным с эффектом левофлоксацина, является ПФК/МПК, а в случае дорипенема параметры T&gt;МПК и ПФК/МПК одинаково хорошо коррелировали с его эффектом. Таким образом, ПФК/МПК можно считать универсальным ФК/ФД параметром, применимым для прогноза эффекта как концентрационно-время-, так и время-зависимых антибиотиков, так как он учитывает оба показателя экспозиции: время и концентрацию.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Antibiotics are classified into «time-dependent», «concentration-dependent», and «concentration-and-timedependent» based on the relationship of their effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) parameters: T &gt;МIC (time of the dosing interval during which the concentration of the antibiotic exceeds MIC), CMAX/MIC (ratio of maximal concentration to MIC), or AUC/MIC (the ratio of the area under the pharmacokinetic curve to MIC), is currently undergoing significant revision.</p></sec><sec><title>The aim of the study</title><p>The aim of the study. Analysis of the relationships between the values of AUC/MIC and T &gt;МIC and the effects of doripenem and levofloxacin against Pseudomonas aeruginosa in an in vitro dynamic model.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Clinical isolates of P. aeruginosa 180 and P. aeruginosa 52 were exposed to doripenem or levofloxacin at different dosing regimens, including the therapeutic ones, in an in vitro dynamic model for 5 consecutive days. The antimicrobial effect was evaluated using the integral parameter AUBC; the relationship between the effect of each antibiotic and AUC/MIC or T&gt;МIC was studied. The presence of a statistically significant dependence proves the ability of the parameter to predict the effect.</p></sec><sec><title>Results</title><p>Results. The maximum antimicrobial effect of doripenem was observed in the setting that simulated the therapeutic dose of the antibiotic, while a comparable effect of levofloxacin was achievable under conditions simulating double therapeutic dose and only for one P. aeruginosa strain. The relationships «effect — AUC/MIC or T&gt;МIC» were described by the Hill equation, in the case of doripenem with equally high r2, and in the case of levofloxacin, a reliable relationship was established only with the AUC/MIC parameter.</p></sec><sec><title>Conclusion</title><p>Conclusion. According to our results, the PK/PD parameter associated with the effect of levofloxacin is AUC/MIC, and in the case of doripenem, the parameters AUC/MIC and T&gt;МIC correlated with its effect equally well. Therefore, AUC/MIC can be considered a universal PK/PD parameter applicable for predicting the effect of both concentration-and-time- and time-dependent antibiotics, since it takes into account both exposure indicators: time and concentration.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>дорипенем</kwd><kwd>левофлоксацин</kwd><kwd>P. aeruginosa</kwd><kwd>динамическая система in vitro</kwd><kwd>зависимость «эффект — ФК/ФД параметр»</kwd></kwd-group><kwd-group xml:lang="en"><kwd>doripenem</kwd><kwd>levofloxacin</kwd><kwd>P. aeruginosa</kwd><kwd>in vitro dynamic model</kwd><kwd>«effect- PK/PD parameter» relationship</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA et al. Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020; 33 (3): e00181-19. doi: 10.1128/CMR.00181-19.</mixed-citation><mixed-citation xml:lang="en">De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA et al. Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020; 33 (3): e00181-19. doi: 10.1128/CMR.00181-19.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019; 6 (2): 109–119. doi: 10.1016/j.gendis.2019.04.001.</mixed-citation><mixed-citation xml:lang="en">Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019; 6 (2): 109–119. doi: 10.1016/j.gendis.2019.04.001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tam VH, Schilling AN, Poole K, Nikolaou M. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007; 60 (6): 1302–9. doi: 10.1093/jac/dkm370.</mixed-citation><mixed-citation xml:lang="en">Tam VH, Schilling AN, Poole K, Nikolaou M. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007; 60 (6): 1302–9. doi: 10.1093/jac/dkm370.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Джекобс М. Новые подходы к оптимизации антимикробной терапии инфекций дыхательных путей с использованием фармакокинетических/фармакодинамических параметров. Клиническая микробиология и антимикробная химиотерапия. 2004; 6 (1): 22–31. Доступно по адресу: Ссылка активна на 10 апреля 2026 г. Dostupno po adresu: Ssylka aktivna na 10 aprelya 2026 g.) https://cmacjournal.ru/publication/2004/1/cmac-2004-t06-n1-p022/. New Approaches to the Optimization of Antimicrobial Therapy of Respiratory Tract Infections Using Pharmacokinetic and Pharmacodynamic Parameters. Clinical Microbiology and Antimicrobial Chemotherapy. 2004; 6(1):22-31[In Russian]. Available at: https://cmac-journal.ru/publication/2004/1/cmac-2004-t06-n1-p022/. Accessed April 10, 2026.</mixed-citation><mixed-citation xml:lang="en">Dzhekobs M. Novye podkhody k optimizatsii antimikrobnoj terapii infektsij dykhatelʹnykh putej s ispolʹzovaniem farmakokineticheskikh/farmakodinamicheskikh parametrov. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2004; 6 (1): 22–31. (In Russ.). Dostupno po adresu: Ssylka aktivna na 10 aprelya 2026 g.) https://cmacjournal.ru/publication/2004/1/cmac-2004-t06-n1-p022/. New Approaches to the Optimization of Antimicrobial Therapy of Respiratory Tract Infections Using Pharmacokinetic and Pharmacodynamic Parameters. Clinical Microbiology and Antimicrobial Chemotherapy. 2004; 6(1):22-31[In Russian]. Available at: https://cmac-journal.ru/publication/2004/1/cmac-2004-t06-n1-p022/. Accessed April 10, 2026.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opin Crit Care. 2015; 21 (5): 412–420. doi: 10.1097/MCC.0000000000000229.</mixed-citation><mixed-citation xml:lang="en">Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opin Crit Care. 2015; 21 (5): 412–420. doi: 10.1097/MCC.0000000000000229.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm. 2009 Jun 15; 66 (12 Suppl 4): S23–30. doi: 10.2146/090087d.</mixed-citation><mixed-citation xml:lang="en">Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm. 2009 Jun 15; 66 (12 Suppl 4): S23–30. doi: 10.2146/090087d.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015; 16 (2): 147–153. doi: 10.1177/1751143714564816.</mixed-citation><mixed-citation xml:lang="en">Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015; 16 (2): 147–153. doi: 10.1177/1751143714564816.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelman B, Craig W. Kinetics of antimicrobial activity. J Pediatr. 1986; (108): 835–40. doi: 10.1016/s0022-3476(86)80754-5.</mixed-citation><mixed-citation xml:lang="en">Vogelman B, Craig W. Kinetics of antimicrobial activity. J Pediatr. 1986; (108): 835–40. doi: 10.1016/s0022-3476(86)80754-5.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis. 1998; 26 (1): 1–10. doi: 10.1086/516284.</mixed-citation><mixed-citation xml:lang="en">Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis. 1998; 26 (1): 1–10. doi: 10.1086/516284.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis. 2003; 7 Suppl 1: S13–20. doi: 10.1016/s1201-9712(03)90066-x.</mixed-citation><mixed-citation xml:lang="en">Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis. 2003; 7 Suppl 1: S13–20. doi: 10.1016/s1201-9712(03)90066-x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi Y, Takahashi M, Sasaki M, Suzuki K, Mizukami Y, Liu X, et al. Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium. J Antimicrob Chemother. 2025; 80 (8): 2092–2099. doi: 10.1093/jac/dkaf175.</mixed-citation><mixed-citation xml:lang="en">Hayashi Y, Takahashi M, Sasaki M, Suzuki K, Mizukami Y, Liu X, et al. Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium. J Antimicrob Chemother. 2025; 80 (8): 2092–2099. doi: 10.1093/jac/dkaf175.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X, Tashiro S,Igarashi Y, Takemura W, Kojima N, Morita T, Hayashi M, Enoki Y, Taguchi K, Matsumoto K. Differences in pharmacokinetic/pharmacodynamic parameters of tedizolid against VRE and MRSA. Pharm Res. 2023; 40 (1): 187–196. doi: 10.1007/s11095-022-03425-5.</mixed-citation><mixed-citation xml:lang="en">Liu X, Tashiro S,Igarashi Y, Takemura W, Kojima N, Morita T, Hayashi M, Enoki Y, Taguchi K, Matsumoto K. Differences in pharmacokinetic/pharmacodynamic parameters of tedizolid against VRE and MRSA. Pharm Res. 2023; 40 (1): 187–196. doi: 10.1007/s11095-022-03425-5.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss WJ, Pulse M, Renick P, et al. Efficacy of fluorocyclines TP-434 in the neutropenic thigh infection model is predicted by AUC/MIC [abstract No. F1-2164 plus poster]. 50th Annual interscience conference on antimicrobial agents and chemotherapy; 12–15 Sep 2010; Boston.</mixed-citation><mixed-citation xml:lang="en">Weiss WJ, Pulse M, Renick P, et al. Efficacy of fluorocyclines TP-434 in the neutropenic thigh infection model is predicted by AUC/MIC [abstract No. F1-2164 plus poster]. 50th Annual interscience conference on antimicrobial agents and chemotherapy; 12–15 Sep 2010; Boston.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019; 63 (9): e02031– 18. doi: 10.1128/AAC.02031-18.</mixed-citation><mixed-citation xml:lang="en">Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019; 63 (9): e02031– 18. doi: 10.1128/AAC.02031-18.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Wu X, Huang Z, Zhang N, Wu Y, Cai Q, Shen X, Ding H. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus peuropneumoniae in a piglet tissue cage infection model. Vet Microbiol. 2018; 219: 100–106. doi: 10.1016/j.vetmic. 2018.02.027.</mixed-citation><mixed-citation xml:lang="en">Zhang L, Wu X, Huang Z, Zhang N, Wu Y, Cai Q, Shen X, Ding H. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus peuropneumoniae in a piglet tissue cage infection model. Vet Microbiol. 2018; 219: 100–106. doi: 10.1016/j.vetmic. 2018.02.027.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic characterization of a novel odilorhabdin antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a murine thigh infection model. Antimicrob Agents Chemother. 2018; 62 (9): e01067–18. doi: 10.1128/AAC.01067-18.</mixed-citation><mixed-citation xml:lang="en">Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic characterization of a novel odilorhabdin antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a murine thigh infection model. Antimicrob Agents Chemother. 2018; 62 (9): e01067–18. doi: 10.1128/AAC.01067-18.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Igarashi Y, Kojima N, Takemura W, Liu X, Morita T, Mizukami Y, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K. In vivo pharmacokinetics/pharmacodynamics profiles for appropriate doses of Cefditoren pivoxil against S. pneumoniae in murine lung-infection model. Pharm Res. 2023; 40 (7): 1789–1797. doi: 10.1007/s11095-023-03539-4.</mixed-citation><mixed-citation xml:lang="en">Igarashi Y, Kojima N, Takemura W, Liu X, Morita T, Mizukami Y, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K. In vivo pharmacokinetics/pharmacodynamics profiles for appropriate doses of Cefditoren pivoxil against S. pneumoniae in murine lung-infection model. Pharm Res. 2023; 40 (7): 1789–1797. doi: 10.1007/s11095-023-03539-4.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Национальный стандарт Российской Федерации ГОСТ Р ИСО 20776-1-2022. Исследование чувствительности инфекционных агентов и оценка функциональных характеристик изделий для исследования чувствительности к антимикробным средствам. Часть 1. Референтный метод микроразведений в бульоне для лабораторного исследования активности антимикробных агентов по отношению к быстрорастущим аэробным бактериям, вызывающим инфекционные заболевания. Ссылка активна на 10 апреля 2026 г. Available at: https://rosgosts.ru/file/gost/11/100/gost_r_iso_20776-1-2022.pdf. Accessed April 10, 2026. Russian.</mixed-citation><mixed-citation xml:lang="en">The national standard of the Russian Federation GOST R ISO 20776-1-2022. Investigation of the susceptibility of infectious agents, and evaluation of the functional characteristics of products for the study of susceptibility to antimicrobial agents. Part 1. A reference method of micro-dilutions in broth for laboratory studies of the activity of antimicrobial agents in relation to fast-growing aerobic bacteria that cause infectious diseases. (In Russ.)]. Available at: https://rosgosts.ru/file/gost/11/100/gost_r_iso_20776-1-2022.pdf. Accessed April 10, 2026. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R.J. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 2009; 49 (7): 798–806. doi: 10.1177/0091270009337012.</mixed-citation><mixed-citation xml:lang="en">Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R.J. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 2009; 49 (7): 798–806. doi: 10.1177/0091270009337012.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997; 32 (2): 101–119. doi: 10.2165/00003088-199732020-00002.</mixed-citation><mixed-citation xml:lang="en">Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997; 32 (2): 101–119. doi: 10.2165/00003088-199732020-00002.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985, 15, 131–137. doi: 10.1093/jac/15.suppl_a.131.</mixed-citation><mixed-citation xml:lang="en">Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985, 15, 131–137. doi: 10.1093/jac/15.suppl_a.131.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Голикова М.В., Струкова Е.Н., Алиева К.Н., Филимонова А.В., Портной Ю.А., Фирсов А.А. Антимутантная эффективность комбинированной терапии дорипенемом и левофлоксацином: исследования в динамических системах in vitro с Pseudomonas aeruginosa. Антибиотики и химиотер. 2021; 66 (3–4): 12–17. doi: https://doi.org/10.37489/0235-2990-2021-66-3-4-12-17.</mixed-citation><mixed-citation xml:lang="en">Golikova MV, Strukova EN, Alieva KN, Filimonova AV, Portnoy YA, Firsov AA. Anti-mutant efficacy of combination therapy with doripenem and levofloxacin: in vitro model studies with Pseudomonas aeruginosa. Antibiot Khimioter = Antibiotics and Chemotherapy. 2021; 66 (3–4): 12–17. (In Russ.). doi: https://doi.org/10.37489/0235-2990-2021-66-3-4-12-17.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1997; 41 (6): 1281–7. doi: 10.1128/AAC.41.6.1281.</mixed-citation><mixed-citation xml:lang="en">Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1997; 41 (6): 1281–7. doi: 10.1128/AAC.41.6.1281.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillinclavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 1998; 42 (9): 2375–2379. doi: 10.1128/AAC.42.9.2375.</mixed-citation><mixed-citation xml:lang="en">Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillinclavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 1998; 42 (9): 2375–2379. doi: 10.1128/AAC.42.9.2375.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Miyazaki S., Okazaki K, Tsuji M, Yamaguchi K. Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models. Antimicrob Agents Chemother. 2004; 48 (2): 378–383. doi:10.1128/AAC.48.2.378-383.2004.</mixed-citation><mixed-citation xml:lang="en">Miyazaki S., Okazaki K, Tsuji M, Yamaguchi K. Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models. Antimicrob Agents Chemother. 2004; 48 (2): 378–383. doi:10.1128/AAC.48.2.378-383.2004.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelman B, Gudmundsson S,Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988; 158 (4): 831–47. doi:10.1093/infdis/158.4.831.</mixed-citation><mixed-citation xml:lang="en">Vogelman B, Gudmundsson S,Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988; 158 (4): 831–47. doi:10.1093/infdis/158.4.831.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother. 1996; 40 (12): 2686–90. doi: 10.1128/AAC.40.12.2686.</mixed-citation><mixed-citation xml:lang="en">Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother. 1996; 40 (12): 2686–90. doi: 10.1128/AAC.40.12.2686.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Strukova EN, Portnoy YA, Golikova MV, Zinner SH. In vitro dynamic model evaluation of meropenem alone and in combination with avibactam against carbapenemase-producing Klebsiella pneumoniae. Pharmaceuticals (Basel). 2024; 17 (12):1683. doi: 10.3390/ph17121683.</mixed-citation><mixed-citation xml:lang="en">Strukova EN, Portnoy YA, Golikova MV, Zinner SH. In vitro dynamic model evaluation of meropenem alone and in combination with avibactam against carbapenemase-producing Klebsiella pneumoniae. Pharmaceuticals (Basel). 2024; 17 (12):1683. doi: 10.3390/ph17121683.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Schentag JJ, Strenkoski-Nix LC, Nix DE, Forrest A. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis. 1998; 27 (1): 40–46. doi: 10.1086/514621.</mixed-citation><mixed-citation xml:lang="en">Schentag JJ, Strenkoski-Nix LC, Nix DE, Forrest A. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis. 1998; 27 (1): 40–46. doi: 10.1086/514621.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012; 56 (5): 2683–90. doi: 10.1128/AAC.06486-11.</mixed-citation><mixed-citation xml:lang="en">Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012; 56 (5): 2683–90. doi: 10.1128/AAC.06486-11.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Wu X, Huang Z, Zhang N, Wu Y, Cai Q et al. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus pleuropneumoniae in a piglet tissue cage infection model. Vet Microbiol. 2018 Jun; 219: 100–106. doi: 10.1016/j.vetmic.2018.02.027.</mixed-citation><mixed-citation xml:lang="en">Zhang L, Wu X, Huang Z, Zhang N, Wu Y, Cai Q et al. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus pleuropneumoniae in a piglet tissue cage infection model. Vet Microbiol. 2018 Jun; 219: 100–106. doi: 10.1016/j.vetmic.2018.02.027.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Firsov AA, Vostrov SN, Shevchenko AA, Zinner SH, Cornaglia G, Portnoy YA. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob Agents Chemother. 1998; 42 (11): 2848–52. doi: 10.1128/AAC.42.11.2848.</mixed-citation><mixed-citation xml:lang="en">Firsov AA, Vostrov SN, Shevchenko AA, Zinner SH, Cornaglia G, Portnoy YA. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob Agents Chemother. 1998; 42 (11): 2848–52. doi: 10.1128/AAC.42.11.2848.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 1998; 42: 657–665. doi:10.1128/AAC.42.3.659.</mixed-citation><mixed-citation xml:lang="en">Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 1998; 42: 657–665. doi:10.1128/AAC.42.3.659.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483–490. doi:10.1128/AAC.37.3.483.</mixed-citation><mixed-citation xml:lang="en">Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483–490. doi:10.1128/AAC.37.3.483.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004; 48 (1): 63–68. doi: 10.1128/AAC.48.1.63-68.2004.</mixed-citation><mixed-citation xml:lang="en">Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004; 48 (1): 63–68. doi: 10.1128/AAC.48.1.63-68.2004.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002 Jun; 19 (6): 546–553. doi: 10.1016/s0924-8579(02)00105-x.</mixed-citation><mixed-citation xml:lang="en">Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002 Jun; 19 (6): 546–553. doi: 10.1016/s0924-8579(02)00105-x.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Andes DR, Craig WA. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis. 1998; 27: 47–50. doi:10.1086/514624.</mixed-citation><mixed-citation xml:lang="en">Andes DR, Craig WA. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis. 1998; 27: 47–50. doi:10.1086/514624.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37: 1073–1081. doi: 10.1128/AAC.37.5.1073.</mixed-citation><mixed-citation xml:lang="en">Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37: 1073–1081. doi: 10.1128/AAC.37.5.1073.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
